Rana 2017.

Methods	Randomised, parallel group trial
Participants	Inclusion criteria Newborn infant with gestation less than 34 weeks N = 100 babies Exclusion criteria Known congenital malformations; serious maternal illnesses (a) severe pre‐eclampsia or eclampsia (b) third stage PPH (c) uncompensated heart disease; twins, triplets or babies requiring resuscitation
Interventions	Intervention: DCC Cord clamping at 120 secs after the birth of baby N = not reported Comparator: ECC Cord clamping within 30 secs after the birth of baby N = not reported
Outcomes	Primary Hyperbilirubinemia and polycythaemia during initial 7 days of life in infants Secondary Requirement for resuscitation Skin temperature at 5 mins and 30 mins of age Incidence of RDS Culture positive or culture negative sepsis Hypoperfusion requiring fluid boluses and/or vasopressors Need for blood transfusion IVH NICU and hospital stay
Notes	No usable data for this review Setting: no information ‐ authors live in India Dates: Started 15 April 2014 but no information on completion date though trial reported as complete on trial registration form. Declaration of interest: not reported Trial funding source: Maulana Azad Medical College (Government Medical College), Bahadur Shah Zafar Marg, New Delhi 110002 Further information: Trial Registration: CTRI/2013/04/003529 We will write to authors for further information, in particular how many were allocated to each group. Previous reporting of this study was under Agarwal 2014, but we consider the Rana 2017 the main publication now.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation (information from trial registration).
Allocation concealment (selection bias)	Low risk	Sequentially numbered, sealed, opaque envelopes (information from trial registration).
Blinding of participants and personnel (performance bias) All outcomes	High risk	Clinicians cannot be blinded.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	There is no information to show that the assessments of outcomes were blinded. For lab tests it is likely there was blinding ‐ but unclear for the clinical outcomes.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information
Selective reporting (reporting bias)	Unclear risk	We did not assess the trial protocol.
Other bias	Unclear risk	There is very little information in this short 'Letter to the Editor'.